Retatrutide Prescribed Online to Vermont Residents
Medical Weight Loss Treatment in Vermont
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Vermont
Vermont's Green Mountains and pastoral landscapes attract people seeking a simpler life—but healthcare access shouldn't be complicated. OmniRx Health serves the entire state, from Burlington's lakeside community to the ski towns of Stowe and Killington, the college town of Middlebury to the Northeast Kingdom's remote beauty. Our telehealth platform brings expert care to every town and village, eliminating the need to navigate mountain roads for medical appointments.
Our providers are licensed by the Vermont Board of Medical Practice to deliver telehealth throughout the Green Mountain State.
Vermont pharmacies in Burlington, Montpelier, and throughout rural communities provide prescription services with statewide delivery.
Vermont has comprehensive telehealth laws that support virtual care while addressing the unique needs of its rural population.
Vermont requires telehealth coverage parity, ensuring virtual visits are covered like in-person appointments.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Vermont?
- Yes, Vermont fully supports telehealth with laws designed to serve its rural population. Licensed providers can offer comprehensive virtual care including prescriptions.
- Can Northeast Kingdom residents use telehealth?
- Telehealth is ideal for Vermont's most remote region. NEK residents can access specialist care without the long drive to Burlington or other urban centers.
- Does Vermont insurance cover telehealth?
- Yes, Vermont mandates telehealth coverage parity. Insurers must cover virtual visits at the same rate as in-person appointments for covered services.